Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Phase 4 Interventional Results available

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Irvine, California • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 27, 2026, 4:09 PM EDT
Terminated Not applicable Interventional

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

NCT04878952
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
Interventions
Garmin Vivofit Activity Tracker
Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacist-Administered Injections for Contraception

NCT00775047
View directory record Official record
Conditions
Contraception
Interventions
Pharmacist-administered, clinic-administered injections
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining Effects of Holistic School Enrichment Programs

NCT05118932
View directory record Official record
Conditions
Mindful Movement Intervention (MMI)
Interventions
Mindful Movement Intervention
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
7 Years to 15 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

NCT00395304
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 27, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 27, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
29
States / cities
Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Active, not recruiting Not applicable Interventional

Parent-Educator Action Response

NCT07203014
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders
Interventions
Parent-Educator Action Response (PEAR), Daily Report Card
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

NCT04535401
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Duarte, California • Bethesda, Maryland • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, Dulaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Tuscumbia, Alabama • Chandler, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 27, 2026, 4:09 PM EDT
Withdrawn Not applicable Interventional

Study of Magnetic Fields to Treat Alzheimer's Disease

NCT01313806
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Resonator, Placebo
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Denver, Colorado • Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

NCT02828358
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 364 Days
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth

NCT01594606
View directory record Official record
Conditions
Conduct Disorder, Depression, Anxiety
Interventions
Animal-assisted intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
14 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mount Clemens, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 27, 2026, 4:09 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

NCT03193047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
bempedoic acid 180mg, placebo, evolocumab
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Not applicable Interventional

New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

NCT00566085
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

NCT04919499
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 765128, Sham comparator
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 3 Interventional

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

NCT00023153
View directory record Official record
Conditions
HIV Infections, Chronic Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 4:09 PM EDT
Completed No phase listed Observational

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

NCT02917057
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide once weekly, basal insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
6,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 27, 2026, 4:09 PM EDT
Completed Phase 4 Interventional

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957
View directory record Official record
Conditions
ADHD, Comorbid Alcohol Abuse
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
El Centro, California • Poway, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 27, 2026, 4:09 PM EDT
Not yet recruiting Phase 4 Interventional

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

NCT07838311
View directory record Official record
Conditions
ADHD, Cannabis Use Disorder
Interventions
Delayed-release, extended-release methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 26 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 4:09 PM EDT